Orexo Forms a Commercial Partnership with Publicis Touchpoint Solutions for launch of Zubsolv™ in the US

Telephone conference today July 1 at 3:00 pm CET
Uppsala, Sweden – July 1, 2013 - Orexo AB announces today that the company has
entered into a commercial partnership with Publicis Touchpoint Solutions for the
launch of Zubsolv in the United States. Preparations for the commercial launch
will commence immediately, in anticipation of the projected approval by the FDA
in early July 2013 with launch in September 2013.

Orexo maintains overall commercial responsibility as part of the agreement, as
well as all rights to Zubsolv in the US market and will consolidate all product
revenue through its subsidiary, Orexo US Inc. Publicis Touchpoint Solutions will
be responsible for the execution of all field-based promotion activities through
dedicated sales representatives and medical support to health care practitioners
through deployment of a dedicated medical scientific liaison team.

The partnership structure secures strong incentives for both Orexo and Publicis
Touchpoint Solutions to maximize the potential of Zubsolv. As part of the
agreement, the companies are sharing the investment and profits in the
commercialization of Zubsolv. After Publicis Touchpoint Solutions has recovered
their investment and agreed return, they will be awarded a single digit share of
the profit until the partnership ends. The partnership is based on a three and a
half year contract that ends in December 2016.

“The selection of Publicis Touchpoint Solutions as a partner to Orexo for the
launch of Zubsolv is the result of a six month comprehensive partnership
assessment and negotiation process. Publicis Touchpoint Solutions is a strong
commercial partner with highly committed leaders that have relevant expertise
from similar product launches, knowledge from the opioid dependence therapeutic
area, and a well-established infrastructure,” says Nikolaj Sørensen, Chief
Executive Officer of Orexo AB.

Publicis Touchpoint Solutions is a leading outsourcing partner to the life
science industry in the US offering their partners comprehensive multichannel
messaging solutions. The company is servicing a multitude of the most successful
pharmaceutical companies in the US.

“Publicis Touchpoint Solutions is an optimal partner to assist us in driving
commercialization of Zubsolv, while we maintain full control of the brand. I am
impressed by the competence and US market insights I have experienced through my
many interactions with Publicis Touchpoint Solutions. Their investment in the
launch of Zubsolv reflects their full commitment to this exciting product,”
continues Nikolaj Sørensen. He also added, “With the innovative partnership
structure, Orexo has limited its financial exposure for launch of Zubsolv. At
the same time, we have gained a partner that is motivated and highly engaged.”

“Publicis Touchpoint Solutions looks forward to partnering with Orexo and
driving successful commercialization of Zubsolv in the US,” says Rick Keefer,
president and CEO of Publicis Touchpoint Solutions. “The strategic plan that
Orexo has established for Zubsolv, including the clinical programs to document
clinical utilization of this novel treatment option in opioid dependent patients
has laid the foundation for a strong commercial launch of the product. Our
venture with Orexo builds on our two organizations’ strengths and dedication,
which in combination with the market opportunity for Zubsolv and the product
features is a strong basis for future commercial success.”

Telephone conference
CEO of Orexo AB Nikolaj Sørensen will together with President of Orexo US Inc.
Robert DeLuca present the background to the agreement with Publicis Touchpoint
Solutions at a teleconference today at 3.00 pm CET.
To participate in the call, please dial: 08-50556477 (SE), +442033645372 (UK) or
+18557161589 (US).
Presentation slides will be available on the website and via the following link:
http://media.fronto.com/cloud/orexo/130701/.

For further information, please contact:
Nikolaj Sørensen, President and CEO
Tel: + 46-703 50 78 88, Email: nikolaj.sorensen@orexo.com

About Zubsolv™
Zubsolv is a novel sublingual formulation of buprenorphine and naloxone using
Orexo’s extensive knowledge in sublingual technologies. Zubsolv is intended for
maintenance treatment of people suffering from opioid dependence. Through
application of its proprietary technologies Orexo has increased the
bioavailability of the active ingredient, accelerated dissolve time, reduced
tablet size and improved taste. In a comparative acceptability study 9 out of 10
participants choose Zubsolv over the market leader Suboxone Film for a daily
treatment. Zubsolv has the potential to be the first new entrant into a growing
USD 1.5 billion market, with more than five million patients suffering from
opioid dependence and where a majority of patients are not adequately treated
today. Market potential for Zubsolv is at peak estimated at above USD 500
million in sales annually.

About Orexo
Orexo is an emerging specialty pharma company developing improved treatments
using proprietary drug delivery technology. Orexo’s expertise is within the area
of reformulation technologies and especially sublingual formulations. The
company has a portfolio of revenue generating EU and US approved products
currently marketed under licence and a pipeline of several reformulations of
approved compounds for areas of unmet medical need. Orexo also has collaboration
projects with several international pharma companies. Orexo, with its
headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are
Novo A/S and HealthCap.

For more information about Orexo AB, please visit www.orexo.com.

About Publicis Touchpoint Solutions, Inc.
Publicis Touchpoint Solutions designs and implements customized, cross-channel,
healthcare sales, service, and clinical communications teams. From in field to
inside and from promotional to clinical, Publicis Touchpoint Solutions centers
-of-excellence include field sales and service, live video detailing, inside
credentialed sales specialists, inside sales and service, clinical health
educators, and medical science liaisons. A wide range of vital support
solutions—each of which serves all of the company’s message delivery
channels—includes recruiting, training, performance management, operations,
data/analytics, and compliance. Publicis Touchpoint Solutions provides the human
touch to precision cross-channel messaging delivered at the right time and
through the right channels to achieve maximum impact. Publicis Touchpoint
Solutions is a member of the Publicis Healthcare Communications Group
(PublicisHealthcare.com).
Website:        www.TouchpointSolutions.com
Twitter:        http://twitter.com/pTouchpoint
LinkedIn:      http://linkd.in/pTouchpoint

Orexo is required under the Financial Instruments Trading Act to make the
information in this press release public. The information was submitted for
publication at 09:30 am CET on July 1, 2013.